Alternative Therapies for Traditional Disease States: Menopause
With growing concern about the use of hormone replacement therapy, some women are looking for alternative treatments for menopausal symptoms and preventing postmenopausal cardiovascular disease and osteoporosis. In observational trials, exercise has been associated with decreased vasomotor symptoms. One trial suggested that black cohosh may reduce menopausal symptoms. Soy has been shown to decrease vasomotor symptoms, lower lipid levels, and increase bone density. However, large amounts of soy must be consumed, and it is not clear whether soy consumption causes a decrease in cardiovascular events or fractures. The evidence for St. John’s wort is equivocal. Fish oil is helpful for secondary prevention of coronary artery disease. (Am Fam Physician 2002;66:129-34. Copyright[C] 2002 American Academy of Family Physicians.)
For most women, menopause is a normal phase of life that does not require medical intervention. However, some perimenopausal women seek treatment for vasomotor symptoms, while postmenopausal women may need treatment that can reduce their risk of cardiovascular disease and osteoporosis. In the United States, one half of perimenopausal women will report feeling irritated or depressed;(1) and about one third will experience dyspareunia, vaginal dryness, or decreased libido. Conventional treatment for menopausal vasomotor symptoms usually consists of hormone replacement therapy (HRT). Prevention of osteoporosis usually consists of HRT, bisphosphonates, selective estrogen receptor modifiers (SERMs), calcitonin, exercise, or calcium and vitamin D supplements. Cardiovascular disease prevention traditionally includes smoking cessation, lowering of lipid levels, blood pressure control, weight control, diabetes management, and exercise. The role of Hrt in this area is still unclear.
Concerns about safety and effectiveness are causing a retreat from the blanket use of HRT. An estimated 30 to 45 percent of women who receive prescriptions for HRT will not have their prescriptions filled or will discontinue therapy within 12 months of initiation.(2) Side effects of breast tenderness and breakthrough bleeding, concerns about breast(3,4)and ovarian cancer,(5,6) gall bladder disease, and thromboembolic events,(7)may all contribute to low adherence rates.
Treating Vasomotor Symptoms
Although 85 percent of perimenopausal women have vasomotor symptoms (hot flushes), only one half of these women find them disturbing.(8) Twenty percent of women will experience symptoms for less than one year, but approximately 50 percent of women may experience symptoms for five years or more.(9) Conventional estrogen therapy is effective in controlling symptoms in more than 90 percent of women.(10)
Although synthetic progesterone (oral and intramuscular injection) has previously been shown to decrease vasomotor symptoms,(11,12) its use has been limited because of side effects and its adverse effect on lipid profiles. The latest randomized trial(13) involving progesterone used progesterone transdermal cream (one-fourth teaspoon or 20 g progesterone cream per day) and found that 83 percent of subjects noted improvement or resolution of vasomotor symptoms in the treatment group, compared with a 19 percent improvement in the placebo group.(13)
Recently, “natural” progesterone extracted from plant sources and “micronized” to enhance its bioavailability has become available. This product has been shown to have no adverse effect on mood or serum high-density lipoprotein (HDL) cholesterol levels.(14) The most common side effects are fatigue and sedation, which can be minimized by taking the drug at bedtime. Despite the benefits of other forms of progesterone in treating vasomotor symptoms, no randomized trials have specifically addressed the effects of micronized progesterone on vasomotor symptoms.
Recent observational studies(15,16) showed that women who regularly exercise are less likely than their sedentary counterparts to experience severe hot flushes. In one observational study of 1,323 women in Sweden,(15) 15 percent of sedentary women experienced “severe” hot flushes, compared with only 5 percent of the subjects who exercised. These differences were not explained by differences in body mass index, smoking habits, or HRT use. However, they may be explained by selection bias.
The consumption of soy has been found to significantly reduce the incidence of hot flushes. In a recent double-blind, placebo-controlled study,(17) hot flushes were reduced by 45 percent in the women who received 60 g of soy protein isolate daily (isoflavone content was not standardized). This reduction was significantly greater than in the subjects who received placebo, although the placebo group also experienced a 30 percent reduction in hot flushes. In one pilot study,(18) a significant reduction in the incidence of hot flushes was found at six weeks in participants who took 400 mg of soy extract and 50 mg isoflavone daily. Other studies have documented significant decreases in the frequency(19) or severity(20) of vasomotor symptoms. Because hot flushes vary in frequency, severity, and duration, future research involving the use of soy should address these variables. The caloric intake of soy must also be considered in the overall health of the patient (Table 1).
Source Soy protein content Approximate calories
1 cup soy milk 3 to 10 g 90 (low fat)
3 oz tofu 10 g 90
11/42 cup soy flour 20 g 220
2 tablespoons soy 25 g 110
protein isolate[*]–Soy lacks cysteine and methionine, and must be combined with
other plant proteins (e.g., rice, corn, wheat) to supply all essential
The mechanism of action of black cohosh is not fully understood. Several studies(21-24) have demonstrated that black cohosh significantly improves menopausal symptoms, but most of these studies had design flaws or were sponsored by the manufacturer. The one double-blind placebo-controlled trial(25) that studied black cohosh was performed in Germany in 1987. The effects of black cohosh (8 mg per day) versus estrogen (0.625 mg conjugated estrogen) and placebo were studied in 80 postmenopausal women. The women in the black cohosh group had a statistically significant improvement in menopausal vasomotor symptoms and vaginal epithelium after 12 weeks. This group also had significantly greater symptom relief than the placebo and estrogen groups. However, contrary to a vast number of earlier studies, this one found that the estrogen group fared no better than the placebo group. This finding calls into question the overall quality and validity of the study.(25) Black cohosh appears to be free of significant side effects and drug interactions.(26) Longterm effects of its use are unknown. In Germany, where the herb is approved for use in treating menopausal symptoms, it is recommended only for short-term (fewer than six months) use.
This root, which has vasodilatory and antispasmodic effects, has been used in Chinese medicine for more than 2,000 years, but it was not scientifically studied until 1997. In one double-blind randomized, placebo-controlled study,(27) 71 women with menopausal symptoms, including hot flushes or night sweats, were assigned to receive dong quai or placebo for 24 weeks. The results showed no significant difference in relief of menopausal vasomotor symptoms between the two groups. The study also showed no difference in endometrial thickness, maturation of vaginal cells, serum estradiol, or estrone levels. The authors concluded that dong quai, when used alone, was no more useful than placebo in the treatment of menopausal symptoms.(27)
Traditional Chinese herbalists have faulted this study because dong quai is not usually used as solo therapy, but is used in conjunction with other herbs. They maintain that the synergistic effect of dong quai acting with other herbs accounts for the beneficial effects. To date, however, it can only be concluded that dong quai used alone is no better than placebo in reducing menopausal vasomotor symptoms.
EVENING PRIMROSE OIL
Evening primrose oil is commonly used for the treatment of menopausal symptoms, but only one randomized trial(28) has studied its effects on menopausal symptoms (MEDLINE search: evening primrose oil/gamolenic acid/ menopause/hot flashes/vasomotor symptoms). This study of 56 symptomatic women found evening primrose oil to be no more effective than placebo in controlling vasomotor symptoms.
Recently published lay and scientific literature has publicized the benefits of antidepressants (e.g., selective serotonin reuptake inhibitors [SSRIs] and St. John’s wort) in the treatment of vasomotor symptoms. The Prescriber’s Letter(29) recently stated that venlafaxine hydrochloride and other SSRIs reduce hot flushes by at least 50 percent. However, a close look at the studies(30,31) reveals that all had design flaws. Even the authors of the studies concluded that SSRIs may be a promising new treatment for vasomotor symptoms, but that well-designed randomized trials are needed before any clinically useful conclusions can be drawn.
When treating menopausal vasomotor symptoms, depression, fatigue, irritability, and fluid retention, herbalists often recommend St. John’s wort. Although the literature supports its use in mild to moderate depression,(32) there is no unequivocal evidence for its use to treat menopausal symptoms.
OTHER HERBAL SUPPLEMENTS AND HOMEOPATHY
There is no good evidence in the literature to support the use of any of the following supplements to treat vasomotor symptoms: flaxseed oil, fish oil, omega-3 fatty acids, red clover, ginseng, rice bran oil, wild yam, calcium, gotu kola, licorice root, sage, sarsaparilla, passion flower, chaste berry, ginkgo biloba, and valerian root. In addition, no studies were found that substantiated the purported effects of homeopathic remedies.(33)
Preventing Cardiovascular Disease
Roughly one half of postmenopausal women die of coronary heart disease (CHD) or stroke, making CHD the leading cause of death in women in this category. Though HRT was once believed to reduce cardiac events, new evidence appears to contradict these earlier observational studies.(34,35) Some discussion of alternative methods to reduce risk in this population is warranted. Of course, traditional risk-reduction measures should also be employed (e.g., smoking cessation, lipid control, weight loss, hypertension and diabetes control).
The U.S. Food and Drug Administration has recently allowed labeling of soy-rich foods as “capable of decreasing the risk of heart disease.” This claim is based on the well-documented lipid lowering effects of soy. One meta-analysis(36) showed a 9 percent decrease in total cholesterol levels and a 13 percent decrease in low-density lipoprotein (LDL) levels in patients taking 50 g of soy per day. However, the role of soy in preventing cardiovascular disease, specifically in postmenopausal women, has yet to be studied. Long-term studies need to be undertaken to determine if this observed lipid-lowering effect translates into a decreased incidence of cardiovascular events and cardiovascular mortality in postmenopausal women.
VITAMINS C, E, AND B CAROTENE
Earlier observational studies seemed to indicate that patients with a higher consumption of vitamins C, E, and B carotene had lower incidences of ischemic heart disease. However, subsequent randomized controlled trials and systematic reviews indicate that no reduction in cardiovascular disease occurs in patients who supplement their diets with vitamins C, E, or B carotene.(37-39) The literature does not specifically address this question with regard to postmenopausal women.
FISH OIL: OMEGA-3 FATTY ACIDS AND N-3 POLYUNSATURATED FATTY ACIDS
All three prospective randomized trials assessing fish oil for the secondary prevention of cardiac events showed positive results.(40-42) In the largest trial,(41) over 11,000 postinfarction patients who received 850 mg of omega-3 fatty acids per day experienced a 45 percent reduction in the rate of sudden cardiac death and a 20 percent reduction in the total mortality rate. What is impressive about this trial is that benefits occurred in patients already receiving “standard” postinfarction therapy (e.g., angiotensin-converting enzyme inhibitors, beta blockers, antiplatelet agents). It is theorized that these effects are the result of the membrane-stabilizing effect of these oils. Though these results are impressive in women with established CHD, no large trials have yet addressed the use of n-3 polyunsaturated fatty acids as a means of primary prevention in postmenopausal women who are at risk (Table 2).(43)
Red clover is sometimes used as an aid to prevent cardiovascular disease. This supplement has been shown to improve systemic arterial compliance and elasticity, an indicator of cardiovascular risk that decreases after menopause.(44) Red clover has not been shown to improve plasma lipids, and it has not been studied long-term to determine if increased arterial compliance leads to a decrease in cardiovascular mortality.
Preventing Bone Loss
It is well documented that the rate of bone loss increases significantly after menopause. Alternative therapies, such as soy and magnesium, may be of benefit.
The effect of soy (i.e., isoflavone) on bone density has recently been evaluated. In one small study,(45) 66 postmenopausal women consumed 40 g of soy protein (standardized to 2.25 mg of isoflavone per g of protein) per day during a six-month trial. The study noted an increase in lumbar spine bone mineral density of 2.2 percent during the study period. No bone density differences were noted in the hip.(45) So far, there have been no studies documenting the role of soy in preventing fractures or increasing hip bone mineral density.
A more recent review(46) concluded that “the data on naturally occurring isoflavones are limited but suggest that including them in diets results in a reduction in bone resorption caused by estrogen deficiency.” Considering the potentially beneficial effects on bone as well as the previously mentioned cardiovascular benefits, it seems that soy in the diet of postmenopausal women could be beneficial.
Magnesium deficiency might also contribute to decreased bone mineral density. Magnesium suppresses parathyroid hormone, which reduces calcium absorption and retention.
Some animal studies(46) suggest that magnesium deficiency might result in decreased bone mineral densities, and other observational studies(47) have shown that elderly patients whose diets have higher intakes of magnesium have increased bone mineral density. However, long-term randomized, placebo-controlled studies evaluating the role of magnesium supplementation in the prevention of osteoporosis and fractures are lacking in the literature.
A magnesium intake of 600 mg per day has been shown to be an adequate amount to maintain bone reserve. However, most dietary surveys conducted in the United States reveal that the average diet contains less than 300 mg of magnesium per day. Table 3(13-17,25,27,28, 32,33,40-48) provides a summary of alternative treatments for menopausal symptoms.
Summary of Alternative Treatments for Menopausal Indications
Vasomotor symptoms: effective Exercise
Vasomotor symptoms: ineffective Dong quai
treatments Evening primrose oil
Vasomotor symptoms:equivocal Ginseng
evidence St. John’s wort
Prevention of cardiovascular Soy
disease: effective treatments Fish oil
Prevention of cardiovascular Red clover
disease: ineffective treatments
Prevention of osteoporosis: Soy
equivocal evidence Magnesium
Agent Summary of evidence
Exercise Observational trials show an
association between exercise and
decreased vasomotor symptoms
Soy One RCT shows efficacy
Black cohosh One RCT of questionable quality
Progesterone Effective, but limited by adverse
Dong quai One RCT shows no efficacy
Evening primrose oil One RCT shows no efficacy
Ginseng No evidence
St. John’s wort Equivocal evidence
Micronized progesterone No evidence
Soy Lowers lipid levels, but no evidence
Fish oil 3 RCTs showing benefit for secondary
Red clover No evidence
Soy May increase bone density; no
evidence on prevention of fractures
Magnesium Observational studies suggest
increase in bone density; no evidence
on prevention of fractures
RCT = randomized controlled trial.
Information from references 13-17,25,27,28,32,33,40-48.
The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.
(1.) Obermeyer CM. Menopause across cultures: a review of the evidence. Menopause 2000;7:184-92.
(2.) Hill DA, Weiss NS, LaCroix AZ. Adherence to postmenopausal hormone therapy during the year after the initial prescription. Am J Obstet Gynecol 2000;182:270-6.
(3.) Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
(4.) Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy. Lancet 1997;350:1047-59.
(5.) Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998;92:472-9.
(6.) Rodriguez C, Patel AV, Calle E, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-5.
(7.) Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72.
(8.) Hacker NF, Moore JG. Essentials of obstetrics and gynecology. 3d ed. Philadelphia: WB Saunders, 1998.
(9.) Israel D, Youngkin EQ. Herbal therapies for perimenopausal and menopausal complaints. Pharmacotherapy 1997;17:970-84.
(10.) Stadberg E, Mattsson LA, Milsom I. The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population. Acta Obstet Gynecol Scand 1997;76:442-8.
(11.) Schiff I, Tulchinsky D, Cramer D, Ryan KJ. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443-5.
(12.) Morrison JC, Martin DC, Blair RA, Anderson GD, Kincheloe BW, Bates GW, et al. The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 1980;138:99-104.
(13.) Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225-8.
(14.) Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy. Am J Obstet Gynecol 1985;151:746-50.
(15.) Ivarsson T, Spetz AC, Hammar M. Physical exercise and vasomotor symptoms in postmenopausal women. Maturitas 1998;29:139-46.
(16.) Stadberg E, Mattsson LA, Milsom I. Factors associated with climacteric symptoms and the use of hormone replacement therapy. Acta Obstet Gynecol Scand 2000;79:286-92.
(17.)Albertazzi P, Pansini F, Bonaccorsi G, Forini E, DeAloysio D. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998;91:6-11.
(18.) Scambia G, Mango D, Signorile PG, Anselmi Aangeli RA, Palena C, Gallo D, et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause 2000;7:105-11.
(19.) Murkies AL, Lombard C, Strauss BJ, Wilcox G, Burger HG, Morton MS. Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas 1995;21:189-95.
(20.) Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999;6:7-13.
(21.) Baker B. Dong Quai, black cohash unproven for menopause. Family Practice News 1999;i5(March 1):25.
(22.)Stolze H. Der andere weg, klimakterische beschwerden zu behandeln. Gync 1982:3:14-16.
(23.) Pethe A. Klimakterische beschwerden, umstellung einer, hormonbehandlung auf ein pflanzliches gynakologikum moglich? Arzt Praxis 1987;38:1551-3.
(24.) Vorborg G. Therapie klimakterischer beschwerden. Erfolgreiche hormonfreie therapie mit remifemin. Z Allgemeinmed 1984;60: 626-9.
(25.) Stoll W. Phytotherapeutikum beeinflusst altrophisches vaginalepithel: Doppelblindvorsuch. Cimicifuga vs. ostrogonpraparat. Therapeuticon 1987;1:23-32.
(26.) Pepping J. Black cohosh: Cimicifuga racemosa. Am J Health Syst Pharm 1999;56:1400-2.
(27.) Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? Fertil Steril 1997;68:981-6.
(28.) Chenoy R, Hussain S, Tayob Y, O’Brien PM, Moss MY, Morse PF. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ 1994;308:501-3.
(29.) Hot flashes. Prescriber’s letter 2000;7:44.
(30.) Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:2377-81. (31.) Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R, et al. A pilot trial assessing the efficacy of
paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17-22.
(32.) Morelli VM, Zoorob RJ. Alternative therapies: Part 1. Depression, diabetes, obesity. Am Fam Physician 2000;62:1051-60.
(33.)Kass-Annese B. Alternative therapies for menopause. Clin Obstet Gynecol 2000;43:162-83.
(34.) Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
(35.) Wenger NK. Lipid management and control of other coronary risk factors in the postmenopausal woman. J Womens Health Gend Based Med 2000;9:235-43.
(36.) Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333:276-82.
(37.) Dagenais GR, Marchioli R, Yusuf S, Tognoni G. Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases. Curr Cardiol Rep 2000;2:293-9.
(38.) Scheen AJ. Antioxidant vitamins in the prevention of cardiovascular diseases. 2nd part: results of clinical trials. Rev Med Liege 2000;55:105-9.
(39.) Christen WG, Gaziano JM, Hennekens CH. Design of physicians’ health study II–a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 2000;10:125-34.
(40.) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999;354:447-55.
(41.) Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction. Lancet 1989;2:757-61.
(42.) Singh RB, Niaz MA, Sharma JP, Kumar R, Rastpgo V, Moshirl M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival–4. Cardiovasc Drugs Ther 1997;11:485-91.
(43.) O’Keefe JH, Harris WS. From inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc 2000;75:607-14.
(44.) Nestel PJ, Pomeroy S, Kay S, Komesaroff P, Behrsing J, Cameron JD, et al. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab 1999;84:895-8.
(45.) Potter SM, Baum JA, Tong H, Stillman RJ, Shay NF, Erdmfan JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68(6 Suppl):1375S-9S.
(46.) Scheiber MD, Rebar RW. Isoflavones and postmenopausal bone health: a viable alternative to estrogen therapy? Menopause 1999;6:233-41.
(47.) Rude RK, Kirchen ME, Gruber HE, Stasky RA, Meyer MH. Magnesium deficiency induces bone loss in the rat. Miner Electrolyte Metab 1998;24:314-20.
(48.) Tucker KL, Hannan MT, Chen H, Cupples LA, Wilson PW, Kiel DP. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am J Clin Nutr 1999;69:727-36.
VINCENT MORELLI, M.D., is an assistant professor in the Department of Family Medicine at the Louisiana State University School of Medicine in New Orleans. He earned his medical degree from the University of Southern California School of Medicine, Los Angeles, and completed a family practice residency at Whittier/USC and a fellowship in sports medicine and arthroscopy in Jonkoping Hospital, Sweden. Dr. Morelli is currently the team physician for the New Orleans Brass hockey team, the New Orleans Zephyrs baseball team, the New Orleans Storm soccer team, and the University of New Orleans.
CHRISTOPHER NAQUIN, M.D., is a resident at the Louisiana State University Family Practice Center and the Louisiana State University Medical Center Family Practice Residency Program in Kenner, Louisiana. He earned his medical degree from the Louisiana State University School of Medicine.
Address correspondence to Vincent Morelli, M.D., LSU Health Sciences Center, Family Practice Residency Program, 200 W. Esplanade Ave., Suite 510, Kenner, LA 70065. Reprints are not available from the authors.
Louisiana State University Health Sciences Center, Kenner, Louisiana
COPYRIGHT 2002 American Academy of Family Physicians
COPYRIGHT 2002 Gale Group